Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012
- Conditions
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2011-11-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT01420458
- Locations
- 🇺🇸
Research Site, Minneapolis, Minnesota, United States
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 889
- Registration Number
- NCT01416181
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2011-11-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT01416207
- Locations
- 🇨🇳
Research Site, Shanghai, China
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 97
- Registration Number
- NCT01416155
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 48
- Registration Number
- NCT01407406
- Locations
- 🇨🇳
Research Site, Hong Kong, Hong Kong, China
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 290
- Registration Number
- NCT01405820
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
- Conditions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 270
- Registration Number
- NCT01405872
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 56
- Registration Number
- NCT01405833
- Locations
- 🇳🇱
Research Site, Leiden, Netherlands
Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 53
- Registration Number
- NCT01397539
- Locations
- 🇺🇸
Compass Research, LLC, Orlando, Florida, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
🇺🇸Insight Clinical Trials, LLC, Beachwood, Ohio, United States
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 41
- Registration Number
- NCT01371305
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States